摘要
心血管疾病已成为危害人类健康与生命的头号死因,每年约有756万人发病,且发病率呈年轻化趋势并逐年上升.近年来,干细胞移植再生医学的出现和迅猛发展拓宽了心血管疾病领域的治疗策略.诱导性多能干细胞(iPSCs)是由已分化的成体细胞重编程诱导产生的一种干细胞类型,其能分化为针对患者自体细胞的特异性治疗细胞,运用疾病特异性iPSCs建立体外疾病模型可以在不受环境因素影响下进行重复分析,目前已用于心血管疾病的分子基础模型研究、移植治疗以及药物筛选.关于iPSCs的研究打开了对心血管疾病治疗和再生医学的新篇章,但该研究尚处于实验探索阶段,在真正了解这项技术之前,是否应该提早将其用于临床?本文就目前对iPSCs的研究现状、存在的问题和解决方法,以及其在心血管疾病方面临床应用的相关新进展作以综述.
Cardiovascular disease has became the first important cause of death,about 7.56 million people were attacked annually,and the trend became younger and increased year by year. Over the past few years,regenerative medicine of stem cell transplantation has expanded the treatment strategy of cardiovascular disease.Induced pluripotent stem cells( iPSCs) are induced by reprogramming adult cells, which can differentiate into patient's specific treatment cells,and using the disease-specific iPSCs to establish a vitro disease model can analyze human cells repeatedly without being affected by environmental factors. It has been used for molecular model of cardiovascular disease, transplantation therapy and drug screening. The study of iPSCs opens a new chapter in cardiovascular disease and regenerative medicine. However,this technology is still in the experimental exploration stage,should it be used in clinical diseases early before total understanding of the technology? This review summarizes the current research status of iPSCs,the existing problems and solutions,as well as its advanced clinical application in cardiovascular disease.
出处
《转化医学电子杂志》
2017年第8期76-81,共6页
E-Journal of Translational Medicine
基金
广东省医学科研基金(A2016392)
广东省科技计划项目(2014A020212234)
中南大学湘雅三医院“新湘雅人才工程”资助项目(JY201524)
关键词
诱导性多能干细胞
重编程
心血管疾病
再生医学
干细胞移植
induced pluripotent stem cells
reprogramming
cardiovascular disease
regenerative medicine
stem cell transplantation